Article Contents ::
- 1 The Brand Name AZONA Has Generic Salt :: ZIPRASIDONE
- 2 AZONA Is From Company Torrent Priced :: Rs. 59.9
- 3 AZONA have ZIPRASIDONE is comes under Sub class Anti Psychotics of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Psychotics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name AZONA Has Generic Salt :: ZIPRASIDONE
AZONA Is From Company Torrent Priced :: Rs. 59.9
AZONA have ZIPRASIDONE is comes under Sub class Anti Psychotics of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Psychotics
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Brand Name||Company / Manufacturers||Strength||Unit||Price / 10|
|Company Brand Name||Salt Combination||Main Medical Class||Sub Medical Class|
|From Torrent :: AZONA||ZIPRASIDONE||Nervous System||Anti Psychotics|
Indications for Drugs ::
Schizophrenia, Bipolar Disorder, Mania
Drug Dose ::
Adult: PO Schizophrenia As HCl: >18 yr: Initial: 20 mg twice daily, may increase slowly to 80 mg twice daily, if needed. Maintenance: 20 mg twice daily. Mania As HCl: Initial: 40 mg twice daily, increase to 60-80 mg twice daily on the 2nd day. Subsequent doses based on patient’s response.
Concomitant use of oral and IM ziprasidone. Recent acute MI, decompensated heart failure, cardiac arrhythmias, conditions that may increase QT interval eg, QT-interval prolongation or history of QT prolongation; prolactin dependent tumours. Lactation. Not for treatment of behavioural disorders in elderly with dementia.
Drug Precautions ::
Patients predisposed to significant electrolyte disturbances, esp hypokalaemia, should have a baseline serum potassium and magnesium screening performed and corrected before treatment. CNS depression; cerebrovascular disease and significant CV illness; history of seizures; conditions that decrease seizue threshold; predisposition to hypotension; patients at risk of aspiration pneumonia; Parkinson’s disease; renal impairment (IM); hepatic impairment; pregnancy. Discontinue if persistent QTc measurements >500 msec. May impair ability to drive or operate machinery. Monitor ECG in patients who shows symptoms of torsades de pointes (e.g. syncope, dizziness, palpitations). Monitor serum electrolytes if on concurrent diuretic therapy. Monitor glucose levels in DM or patient at risk of developing DM.
Drug Side Effects ::
Somnolence, respiratory tract infections, akathisia, extrapyramidal syndrome, tardive dyskinesia, hyperglycaemia, dizziness, dystonia, headache, GI disturbances, asthenia, agitation, rash, urticaria, visual disturbances, prolonged QT interval, orthostatic hypotension, increased prolactin levels, weight gain, sexual dysfunction, hyperlipidaemia, seizures. Potentially Fatal: Blood dyscrasias, neuroleptic malignant syndrome.
Pregnancy category ::
Drug Mode of Action ::
Ziprasidone, an atypical antipsychotic, produces antischizophrenic effect through a combination of dopamine D2 and serotonin 5H2 receptor antagonism.
Drug Interactions ::
Antagonistic effect with levodopa and dopamine antagonists. Additive hypotensive effect with antihypertensives. Additive sedative effects with other CNS agents, alcohol. Potentially Fatal: Increased risk of torsades de pointes with drugs that prolong QT interval e.g. dofetilide, quinidine, sotalol, and other Class Ia and III antiarrhythmics, moxifloxacin, pimozide, sparfloxacin, thioridazine.